Imbruvica - direct healthcare professional communication (DHPC)

Ibrutinib
DHPCHuman

Slovak is available via eTranslation, the European Commission's machine translation service.

Translate to Slovak | Important information about machine translation

Informácie o

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Dokumenty

Direct healthcare professional communication (DHPC): Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events

English (EN) (180.07 KB - PDF)

Prvýkrát uverejnené:
Zobraziť

Key facts

Medicine name
Imbruvica
Active substance
Ibrutinib
Therapeutic area (MeSH)
  • Lymphoma, Mantle-Cell
  • Leukemia, Lymphocytic, Chronic, B-Cell
Procedure number
EMEA/H/C/003791/II/0075
Regulatory outcome
Variation
DHPC type
Post-authorisation measure
Human ATC codes
L01EL01
Dissemination date

Share this page